search
Back to results

Ventilator Aspiration With PneuX (PneuX vs Standard Care Feasibility RCT) (VAP-X)

Primary Purpose

Ventilator Associated Pneumonia, Aspiration, Infections

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
PneuX Endotracheal Tube
Standard care (Taperguard, Covidien)
Sponsored by
Cardiff and Vale University Health Board
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Ventilator Associated Pneumonia focused on measuring Ventilator Associated Pneumonia, endotracheal tube, Aspiration

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years old (no upper age)
  • Patient required endotracheal intubation
  • Expect to remain intubated for 24 hours post randomisation

Exclusion Criteria:

  • The person intubating the patient assesses that the patient has already aspirated.
  • GCS 7 or less on presentation to hospital
  • Patient is pregnant
  • Patient has tracheostomy
  • Patient has gastrectomy
  • Patients who have been intubated prior to arrival at hospital
  • Patients who are already endotracheally intubated and require a tube change.

Sites / Locations

  • University Hospital of WalesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PneuX endotracheal tube

Standard care

Arm Description

Patients will be intubated using the PneuX endotracheal tube system

Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).

Outcomes

Primary Outcome Measures

To assess if a recruitment rate of 50 patient annually is achievable and identify any barriers to recruitment
The recruitment rate will be assessed using the "screening and recruitment log" which will record the number of patients recruited each month and reasons for non-recruitment will be described

Secondary Outcome Measures

To assess the feasibility of delivering the study intervention
Any issues experienced when using the study device at any point during the study will be recorded in the CRF, including device-related complications.
Number of participants with a failed pepsin test
Any issues such as failed sampling or failed testing will be recorded in case report form
Number of participants with a positive pepsin tracheal aspirate sample using Peptest
The proportion of tracheal aspirate samples which are positive for the presence of pepsin using the Peptest test
Volume of sub-glottic aspirates
The volume of the sub-glottic aspirates will be measured every 24 hours
Rate of tracheobronchial colonization
Tracheobronchial colonization (no. colony forming units/ml) present in sputum samples will be measured by culture on days 3 and 7
Proportion of patients who require antibiotics
The following will be assessed: antibiotic prescribed, indication for use, number of days administered
Rate of Ventilator Associated Pneumonia (VAP)
Number of patients with VAP diagnosis. Clinical Pulmonary Infection Score (CPIS) used to predict VAP. CPIS >6 will be used to define confirmation of VAP. Measured daily after 48 hours of intubation
Time spent on the ventilator
Days spent with mechanical ventilation in ICU (from time/date of intubation to time/date of extubation or 28 days)
Number of days spent in ICU and hospital
Length of stay in ICU and length of stay in hospital measured in days from ventilation
Rate of in-hospital mortality
Number of patients who die in hospital up to 28 days after entry into ICU
Rate of compliance with measuring and documenting cuff pressure
Documentation of cuff pressures in both arms of study. Cuff pressure in standard care will be measured every 12 hours. Assessment of intervention arm will have documentation that pressure has been maintained hourly either via the continual cuff pressure monitor or manually.

Full Information

First Posted
May 18, 2022
Last Updated
August 30, 2023
Sponsor
Cardiff and Vale University Health Board
Collaborators
Cardiff University
search

1. Study Identification

Unique Protocol Identification Number
NCT05410106
Brief Title
Ventilator Aspiration With PneuX (PneuX vs Standard Care Feasibility RCT)
Acronym
VAP-X
Official Title
A Single Centre, Open-label, Feasibility Randomised Controlled Trial to Evaluate Gastric Microaspiration in Critically Ill Patients Intubated Using the Venner PneuX System Compared to Standard of Care Using Pepsin Biomarker (VAP-X)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 5, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cardiff and Vale University Health Board
Collaborators
Cardiff University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a single centre, open-label, feasibility randomised controlled trial. The study aims to assess the feasibility of conducting an RCT to compare the PneuX ETT with standard care in hospitalised patients requiring mechanical ventilation. The patient population for this study are those who are experiencing critical illness requiring intubation and ventilatory support. Patients will be randomised in equal proportions into one of 2 arms: to be intubated using a Venner PneuX Endotracheal Tube (ETT) or using the standard tube. For this feasibility study, a total of 50 patients will be randomised into two groups (25 in each). All patients will be recruited at a single site (University Hospital of Wales, part of Cardiff & Vale UHB). The study will investigate several feasibility measures including recruitment, delivery of the intervention (including device-related adverse events), acceptability and adherence to the intervention and sampling, use of Peptest to measure microaspiration events, rate of pepsin positive samples, rate of tracheobronchial colonisation, volume of sub-glottic aspirate, rate of VAP, length of ICU and hospital stay, demonstrate the validity of study documentation and provide preliminary data for 50 patients. The data will inform the pilot and main phase of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator Associated Pneumonia, Aspiration, Infections, Ventilator Lung
Keywords
Ventilator Associated Pneumonia, endotracheal tube, Aspiration

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Feasibility, 2-arm, parallel, randomised controlled trial
Masking
Participant
Masking Description
Due to the nature of the interventional device it is not possible to blind the care providers or outcome assessors to the intervention group. The trial participants will be unconscious/sedated for the duration of the period that the PneuX device or standard ETT is in place and therefore will be unaware of their allocation. Samples sent to the laboratory for analysis will be anonymised using individual deidentified numbers for each participant.
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PneuX endotracheal tube
Arm Type
Experimental
Arm Description
Patients will be intubated using the PneuX endotracheal tube system
Arm Title
Standard care
Arm Type
Active Comparator
Arm Description
Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
Intervention Type
Device
Intervention Name(s)
PneuX Endotracheal Tube
Other Intervention Name(s)
Venner PneuX System
Intervention Description
The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
Intervention Type
Device
Intervention Name(s)
Standard care (Taperguard, Covidien)
Intervention Description
Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
Primary Outcome Measure Information:
Title
To assess if a recruitment rate of 50 patient annually is achievable and identify any barriers to recruitment
Description
The recruitment rate will be assessed using the "screening and recruitment log" which will record the number of patients recruited each month and reasons for non-recruitment will be described
Time Frame
Through study completion, an average of 1 year
Secondary Outcome Measure Information:
Title
To assess the feasibility of delivering the study intervention
Description
Any issues experienced when using the study device at any point during the study will be recorded in the CRF, including device-related complications.
Time Frame
Duration of study treatment (typically 4-7 days)
Title
Number of participants with a failed pepsin test
Description
Any issues such as failed sampling or failed testing will be recorded in case report form
Time Frame
Duration of study treatment (typically 4-7 days)
Title
Number of participants with a positive pepsin tracheal aspirate sample using Peptest
Description
The proportion of tracheal aspirate samples which are positive for the presence of pepsin using the Peptest test
Time Frame
Duration of study treatment (typically 4-7 days)
Title
Volume of sub-glottic aspirates
Description
The volume of the sub-glottic aspirates will be measured every 24 hours
Time Frame
Duration of study treatment (typically 4-7 days)
Title
Rate of tracheobronchial colonization
Description
Tracheobronchial colonization (no. colony forming units/ml) present in sputum samples will be measured by culture on days 3 and 7
Time Frame
Duration of study treatment (typically 4-7 days)
Title
Proportion of patients who require antibiotics
Description
The following will be assessed: antibiotic prescribed, indication for use, number of days administered
Time Frame
28 days
Title
Rate of Ventilator Associated Pneumonia (VAP)
Description
Number of patients with VAP diagnosis. Clinical Pulmonary Infection Score (CPIS) used to predict VAP. CPIS >6 will be used to define confirmation of VAP. Measured daily after 48 hours of intubation
Time Frame
28 days
Title
Time spent on the ventilator
Description
Days spent with mechanical ventilation in ICU (from time/date of intubation to time/date of extubation or 28 days)
Time Frame
Duration of study treatment (typically 4-7 days)
Title
Number of days spent in ICU and hospital
Description
Length of stay in ICU and length of stay in hospital measured in days from ventilation
Time Frame
28 days
Title
Rate of in-hospital mortality
Description
Number of patients who die in hospital up to 28 days after entry into ICU
Time Frame
28 days
Title
Rate of compliance with measuring and documenting cuff pressure
Description
Documentation of cuff pressures in both arms of study. Cuff pressure in standard care will be measured every 12 hours. Assessment of intervention arm will have documentation that pressure has been maintained hourly either via the continual cuff pressure monitor or manually.
Time Frame
Duration of study treatment (typically 4-7 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years old (no upper age) Patient required endotracheal intubation Expect to remain intubated for 24 hours post randomisation Exclusion Criteria: The person intubating the patient assesses that the patient has already aspirated. GCS 7 or less on presentation to hospital Patient is pregnant Patient has tracheostomy Patient has gastrectomy Patients who have been intubated prior to arrival at hospital Patients who are already endotracheally intubated and require a tube change.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Judith White
Phone
02921844771
Email
judith.white3@wales.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Rhys Morris
Phone
0292144772
Email
Rhys.Morris@wales.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Wise
Organizational Affiliation
Cardiff and Vale University Health Board
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Matthew Wise
Organizational Affiliation
Cardiff and Vale University Health Board
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Wales
City
Cardiff
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jade Cole
Phone
029 21 843608
Email
Jade.Cole@wales.nhs.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ventilator Aspiration With PneuX (PneuX vs Standard Care Feasibility RCT)

We'll reach out to this number within 24 hrs